Gus Bilirakis advances bills to expand research and access

Gus Bilirakis – Two Bilirakis proposals cleared a House panel unanimously, aiming to expand stem cell transplant access and accelerate ALS therapies.

Congress is moving to expand medical research and widen patient access to potential therapies, as U.S. Rep. Gus Bilirakis advanced two bills focused on diseases that have few reliable treatment options.

The two measures cleared the House Energy & Commerce’s Health Subcommittee unanimously. placing them on a fast track through the committee process.. Bilirakis. a Palm Harbor Republican. framed the progress as part of a broader push to keep momentum in medical innovation while improving access for patients and families facing conditions that can be especially relentless.

One bill would extend federal support for stem cell and transplant programs.. The Stem Cell Therapeutic and Research Reauthorization Act (HR 5160) is designed to move forward as part of reauthorizing the C.W.. Bill Young Cell Transplantation Program, named for the longtime Tampa Bay Republican C.W.. “Bill” Young, who died in 2013.. Bilirakis led the effort along with GOP Reps.. Chris Smith of New Jersey and Claudia Tenney of New York, and Democratic Reps.. Doris Matsui of California, Chellie Pingree of Maine, and Kweisi Mfume of Maryland.

Bilirakis tied the legislation to the widespread impact of illnesses that can require bone marrow or cord blood transplants.. He noted that thousands of Americans are diagnosed each year with diseases including leukemia and lymphoma. as well as sickle cell disease and other inherited immune system disorders.. For many patients. a transplant can be a critical treatment option. but finding a compatible donor remains a major barrier. especially when a matching donor is not available within a patient’s own family.

Under the measure, the reauthorization would fund national cord blood and bone marrow transplant programs. It reauthorizes more than $280 million over five years, continuing federal backing for efforts intended to improve the availability of transplant resources.

The second bill focuses on amyotrophic lateral sclerosis, or ALS, often referred to as Lou Gehrig’s disease. The Accelerating Access to Critical Therapies for ALS Reauthorization Act (HR 8205) was also approved unanimously by the subcommittee.

Bilirakis described ALS as a devastating illness that gradually restricts a person’s ability to move. speak. eat. and breathe. while emphasizing that there is still no cure.. For many families. he said. the challenge is not only medical but also temporal: patients cannot wait through prolonged research cycles and extended regulatory timelines.

That urgency is central to the history of the policy.. Bilirakis pointed to Congress’s decision to pass ACT for ALS in 2021. which was built around accelerating research. improving coordination. and expanding access to promising investigational therapies.. He said that program has helped strengthen collaboration among researchers. regulators. manufacturers. and patient advocates as stakeholders work to better understand and treat ALS.

HR 8205 would continue those efforts without interruption while adding stronger oversight requirements. Bilirakis said the legislation would bolster spending review by requiring action plans from the Food and Drug Administration and by prompting review of drug and treatment trials.

With both bills clearing the Health Subcommittee unanimously. the measures are now positioned to advance through the next stages of House committee consideration—potentially bringing renewed momentum to federal efforts aimed at both transplant access for blood and immune disorders and faster development pathways for ALS therapies.

Gus Bilirakis HR 5160 HR 8205 stem cell reauthorization ALS research cord blood transplant House Energy and Commerce